本站

本站自营/精选产品 www.yeasen.com | 价格与库存以本站实时信息为准

本站精选 · 品质自营查看原始页面 ›

Vendor Tel：400-6111-883

Product data sheet PD-40183ES

Enquiry

Tell us your volume and application; we reply with a quote.

Start enquiry

In stock Microbiology & Culture Media 翌圣生物 Yeasen

Ceturegel® Matrix LDEV-Free基质胶

Scan for product

类器官研究肿瘤研究细胞培养基因表达研究

Product no.40183ES Sizes3 options SourceYeasen · Official

Cat. No. 40183ES08

现货

Qty 1

Enquire now

Enquire / bulk Compare

Specifications & Enquiry

Tick the specs you need to submit them together; or enquire one by one. Cat. numbers are carried into the RFQ.

Cat.No Spec Price Status

40183ES08 5 mL ¥1,358.00促~~¥1,855.00~~ 现货 Enquire

40183ES10 10 mL ¥2,458.00促~~¥3,355.00~~ 现货 Enquire

40183ES00 1.5 mL Ask 咨询 Enquire

Submit enquiry Price is on application; bulk sizes can be sampled on request.

Overview

Specifications

Brand翌圣生物 Yeasen

Cat.No40183ES

Specification1、无污染：通过严格透析除菌，保证无细菌和真菌生长2、蛋白浓度：浓度8~20 mg/ml3、内毒素残留：含量<8EU/ml4、安全性高：不含LDEV残留5、产量高：单月产量在50L级别以上6、支原体残留：检测验证无支原体污染

Origin翌圣生物科技(上海)股份有限公司

应用方法 类器官研究用于类器官培养 肿瘤研究用于肿瘤细胞侵袭和成瘤模型 细胞培养支持细胞体外培养和分化 基因表达研究影响三维培养物的基因表达

适用物种种属小鼠

生物特性参数 细胞产品子类基质胶 适用细胞类型上皮细胞、肝细胞、塞尔托利氏细胞、黑色素瘤细胞、血管内皮细胞、甲状腺细胞、毛囊细胞等 来源物种小鼠 产品形式液体 主要成分层粘连蛋白、IV型胶原、硫酸乙酰肝素蛋白聚糖、巢蛋白等 生长因子TGF-beta、EGF、IGF、FGF等 应用范围细胞培养、类器官培养、肿瘤研究等

技术参数浓度8-20 mg/mL 无菌性无菌 支原体检测无支原体污染 内毒素残留<8 EU/mL LDEV残留不含LDEV残留 储存条件-20℃保存，有效期两年 运输条件干冰运输

实验类型 3D细胞培养模拟体内细胞基底膜结构，促进细胞贴壁与分化 细胞侵袭实验用作肿瘤细胞侵袭研究的基本支架 体内成瘤实验作为移植瘤细胞生长的三维支架 血管新生研究体内外血管新生研究必不可少的基质 外周神经再生研究支持外周神经的新生

FAQ

Q:基质胶使用浓度？

A：凝胶浓度：在需要基质胶凝胶的实验中，工作浓度需大于3 mg/mL

包被浓度：包被实验时基质胶无需成胶，因此包被浓度应小于凝胶浓度（即3mg/mL），工作浓度需要根据具体的细胞类型进行预实验测试。对于侵袭实验，建议浓度设置在1-2mg/mL之间，再根据特定的实验体系进行优化

血管生成实验浓度：请务必使用大于10 mg/mL的基质胶产品

体内皮下注射实验浓度：由于是体内实验，为了避免成胶不完全，建议终浓度在4 mg/mL以上

3D培养：建议终浓度在4 mg/mL以上

Q：40183应用方向？

A：适应于2D和3D培养、侵袭和迁移实验，也可以用于体内成瘤实验

Q：40183与40184的区别？

A：40184是无酚红的，40183是含酚红的

Q：基质胶的保存温度，可以放-80保存吗？

A：可以的，-20和-80均是可以的

Q：基质胶中LDEV是什么？

A：乳酸脱氢酶增高病毒（LDEV）会感染小鼠巨噬细胞，并导致实验室小鼠群体的持续性感染。LDEV是一类RNA病毒，会改变小鼠的体内生理活动，是源自可移植肿瘤细胞系的生物试材的常见污染物。

Documents & Citations

Published citations

[1] Jia, D., Wang, Q., Qi, Y., Jiang, Y., He, J., Lin, Y., Sun, Y., & Wang, L. (2024). Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell, *187*(7), 1651-1665.e21. doi: 10.1016/j.cell.2024.02.022 (IF:64.5)

[2] Ren, W., Zheng, P., Zhou, Z., et al. (2025). Immunoglobulin-directed phase separation for cell-specific modulation of receptor signaling. Journal of the American Chemical Society, *147*(38), 34620-34631. doi: 10.1021/jacs.5c09699 (IF:15.7)

[3] Zhao, T., Jin, K., Wang, X. et al. GPAT4 sustains endoplasmic reticulum homeostasis in endocardial cells and safeguards heart development. Nat Commun 16, 3345 (2025).. doi: 10.1038/s41467-025-58722-5 (IF:15.7)

[4] Zhao, S., Liu, X., Luo, R., et al. (2025). USP38 functions as an oncoprotein by downregulating the p53 pathway through deubiquitination and stabilization of MDM2. Cell Death & Differentiation, *32*, 1128-1141. doi: 10.1038/s41418-025-01462-2 (IF:15.4)

[5] Zhao, K., Sun, T., Sun, Q., Chen, Z., Wang, T., Yang, J., Li, L., Zhu, Y., Liu, X., Yang, D., Lin, B., & Lu, N. (2025). Nerve growth factor signaling promotes nuclear translocation of TRAF4 to enhance tumor stemness and metastatic dormancy via c-Jun-mediated IL-8 autocrine. Advanced Science, *12*, 2414437. doi: 10.1002/advs.202414437 (IF:15.1)

[6] Hu, L., Ma, X., Cai, X., et al. (2026). The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer. Cell Discovery, *12*, 17. doi: 10.1038/s41421-026-00880-x (IF:13)

[7] Wu, C., Sun, X., Lu, Y., et al. (2025). Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1/miR-200a-3p/MKP1 axis-mediated apoptosis suppression. Journal of Experimental & Clinical Cancer Research, *44*, 274. doi: 10.1186/s13046-025-03529-x (IF:12.8)

[8] Nan, Y., Zhu, M., Wang, Q., Du, X., Xu, C., & Wan, Y. (2025). Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models. Molecular Therapy, *33*(10), 4988–5002. doi: 10.1016/j.ymthe.2025.07.004 (IF:12.1)

[9] Xiao, F., Zhu, H., Xiong, Y., Guo, Y., Zhang, Z., Zeng, J., Xiao, Y., Liao, B., Shang, X., Zhao, S., Hu, G., Huang, K., & Guo, H. (2024). Positive feedback loop of c-myc/XTP6/NDH2/NF-κB to promote malignant progression in glioblastoma. Journal of Experimental & Clinical Cancer Research, *43*(1), 187. doi: 10.1186/s13046-024-03109-5 (IF:11.4)

[10] Zhou, X., Wang, J., Lu, M., Fang, L., Zhao, J., & Li, D. (2025). Leucine-rich repeat-containing 56 promotes breast cancer progression via modulation of the RhoA/ROCKs signaling axis. Molecular Biomedicine, *6*(1), 31. doi: 10.1186/s43556-025-00271-w (IF:10.1)

[11] Dong, D., Wang, Z., Liu, M., et al. (2025). Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus. Nature Communications, *16*, 8950. doi: 10.1038/s41467-025-64005-w (IF:10)

[12] Yang, N., & Li, X. (2022). Epigallocatechin gallate relieves asthmatic symptoms in mice by suppressing HIF-1α/VEGFA-mediated M2 skewing of macrophages. Biochemical Pharmacology, *202*, 115112. doi: 10.1016/j.bcp.2022.115112 (IF:5.858)